TNF Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)							12 Months Ended
Equity (Details Narrative) - USD ($)	Feb. 16, 2022	Dec. 09, 2021	Aug. 05, 2021	May 18, 2021	Feb. 11, 2021	Mar. 24, 2020	Dec. 31, 2021	Dec. 31, 2020	Apr. 16, 2021	Apr. 15, 2021
Class of Stock [Line Items]
Preferred stock, shares authorized							50,000,000	50,000,000
Preferred stock, no par value							$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		11,576					11,576
Options exercise price		$ 2.59					$ 2.59	$ 2.59
Proceeds from stock option exercise		$ 29,982
Proceeds from warrant exercise							$ 1,189,840
Merger Agreement [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized									500,000,000	100,000,000
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Number of shares issued					466,216
Common Stock [Member]
Class of Stock [Line Items]
Shares underlying							36,496
Exchange of sommon stock				466,716
Shares issued for services			16,826
Fair market value of shares issued for services			$ 90,002
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							11,576
Common Stock [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	385,135
Pre-funded Warrants [Member]
Class of Stock [Line Items]
Number of warrants exercised				466,216
Pre-funded Warrants [Member] \| Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Warrants issued					466,216
Common Stock Warrants [Member]
Class of Stock [Line Items]
Number of warrants exercised							289,058
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 6.06
Common Stock Warrants [Member] \| Warrant Holders [Member]
Class of Stock [Line Items]
Number of warrants exercised							289,058
Proceeds from warrant exercise							$ 1,189,840
Pre Funded Common Stock Warrants [Member]
Class of Stock [Line Items]
Number of warrants exercised							466,216
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 6.06
Warrant [Member] \| Warrant Holder [Member] \| Subsequent Event [Member]
Class of Stock [Line Items]
Number of warrants exercised	385,135
Series C Convertible Preferred Stock Warrants [Member]
Class of Stock [Line Items]
Number of warrants exercised
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 6.06
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized						211,353
Preferred stock, no par value						$ 0
Preferred stock, stated value per share						0.01
Debt instrument convertible conversion price						$ 0.01
Conversion of stock, description						A holder of Preferred Stock will be prohibited from converting Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding (with such ownership restriction referred to as the “Beneficial Ownership Limitation”). However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to the Company.
Preferred stock, shares outstanding							72,992